What are the adverse effects of amiodarone?

Amiodarone Side Effects

Amiodarone causes serious multi-organ toxicity requiring systematic monitoring, with pulmonary toxicity being the most life-threatening adverse effect, occurring in 1-17% of patients and potentially progressing to fatal adult respiratory distress syndrome. 12

Major Organ System Toxicities

Pulmonary Toxicity (Most Serious)

• Incidence: 1-17% in long-term therapy, 1% annually in controlled trials 13
• Presentation: Subacute cough and progressive dyspnea with patchy interstitial infiltrates on chest X-ray and reduced diffusing capacity 1
• Mechanism: Direct drug-induced phospholipidosis or immune-mediated hypersensitivity 1
• Critical pitfall: Can develop rapidly with no antecedent abnormalities on baseline imaging—routine screening has limited value 1
• Management: Immediate amiodarone withdrawal, supportive care, and corticosteroids in some cases; usually reversible if caught early 1

Thyroid Dysfunction

• Incidence: 15-20% of patients overall 4
  • Hypothyroidism: More common (2-4 times more frequent than hyperthyroidism) 1
  • Hyperthyroidism: 0.9-2% 3
• Mechanism: High iodine content (structural similarity to thyroxine) affects thyroid function 1
• Management approach:
  • Hypothyroidism: Continue amiodarone with levothyroxine supplementation 14
  • Hyperthyroidism: May require antithyroid medications, prednisone, or surgical thyroidectomy 1

Hepatotoxicity

• Incidence: Elevated transaminases in 15-30%; hepatitis/cirrhosis <3% (0.6% annually) 13
• Presentation: Usually asymptomatic elevation of ALT, AST, and GGT 1
• Action threshold: Discontinue if liver enzymes exceed 3 times upper normal limit, unless patient is at high risk for life-threatening arrhythmia recurrence 1
• Important note: Baseline liver enzyme abnormalities are NOT a contraindication to treatment 1

Cardiovascular Effects

• Bradycardia/heart block: 1-3% with oral therapy; 4.9% with IV administration 11
• Hypotension: Most common IV adverse effect (16% of patients), typically occurs in first several hours, rate-related not dose-related 22
• Proarrhythmia: <1% annually; torsades de pointes is rare despite universal QT prolongation 1
• IV-specific: Heart block/bradycardia in 4.9%, hypotension in 16% of IV patients 1

Ocular Toxicity

• Corneal microdeposits: >90% of patients on slit-lamp examination; rarely affect vision or require discontinuation 13
• Optic neuropathy/neuritis: ≤1-2%, can progress to total blindness 3
• Action required: Any visual acuity or peripheral vision changes mandate immediate ophthalmologic evaluation 1

Dermatologic Effects

• Photosensitivity: 25-75% of patients 3
• Blue-gray skin discoloration: 4-9%, occurs with extended sun exposure in exposed areas; resolves over months after discontinuation 13
• Severe reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis (sometimes fatal), exfoliative dermatitis 2

Neurologic Toxicity

• Peripheral neuropathy: 0.3% annually 11
• Other effects: Ataxia, paresthesias, tremor—typically dose-related and improve with dose reduction 11

Gastrointestinal Effects

• Common: Nausea, anorexia, constipation—dose-related and improve with dose reduction 1

Route-Specific Differences

Recent pharmacovigilance data reveals distinct adverse event profiles:

• IV administration: Cardiac and hepatic events predominate; median onset 5 days 5
• Oral administration: Pulmonary and thyroid events more common; median onset 74 days 5
• Both routes: Show early failure-type signals with decreasing risk over time 5

Critical Drug Interactions

Warfarin

• Effect: Sudden, pronounced increases in PT/INR 11
• Peak interaction: 7 weeks after initiation 11
• Monitoring: PT/INR at least weekly during first 6 weeks 11

Digoxin

• Effect: Levels predictably double due to inhibited renal tubular secretion 11
• Action: Reduce digoxin dose by 50% when starting amiodarone 1
• Peak interaction: 7 weeks after initiation 1

Other significant interactions

• Inhibits CYP 2C9, CYP 2D6, and CYP 3A4 pathways 1
• Affects beta blockers, calcium channel blockers, cyclosporine, statins, HIV antiretrovirals 16
• Grapefruit juice: Inhibits metabolism; patients must avoid 1

Mandatory Monitoring Protocol

Baseline assessment: 11

• Complete history/physical (heart failure, arrhythmia symptoms, medications)
• Chest radiograph
• Thyroid studies and liver transaminases
• Pulmonary function tests including DLCO
• Digoxin level, PT/INR (if applicable)
• Ophthalmologic exam (if preexisting visual impairment)

During loading phase:

• Close heart rate surveillance (especially first week)
• History/physical for anticipated adverse effects

Every 6 months: 11

• Thyroid studies and liver transaminases
• History/physical directed at adverse effects
• Digoxin level (if applicable)

As clinically indicated:

• Chest X-ray and PFTs for suspected pulmonary toxicity
• Ophthalmologic exam for visual symptoms

Key Clinical Principles

Use lowest effective dose: Toxicity frequency relates to total drug exposure (dose × duration) 1

Long half-life implications: Average 58 days; adverse effects can develop or persist long after discontinuation due to lipid tissue storage 11

Contraindications: Second- or third-degree heart block without pacemaker 1

Special populations: Crosses placenta and reaches measurable levels in breast milk 1

The evidence consistently demonstrates that while amiodarone is highly effective for arrhythmia control, its use requires vigilant monitoring and a clear understanding that serious, potentially fatal toxicities can affect virtually any organ system. The decision to use amiodarone must weigh these substantial risks against the mortality benefit in appropriate clinical scenarios.